Public consultations on Asian Century country strategies
30 April, 2013Australia’s position in the Asia-Pacific region, in what has been dubbed the Asian Century, means biotechnology is poised in the right industry in the right region.
Elastic patch supports cardiac cell growth
30 April, 2013Scientists are a step closer to being able to repair damaged human heart tissue thanks to a world-leading research collaboration between the University of Sydney and Harvard University.
Registrations open for AusBiotech 2013
26 April, 2013The biggest Australian biotechnology event for the year, the AusBiotech 2013 national conference, will be held from 29 October-1 November in Brisbane. Registrations are now open.
ResMed launches home COPD treatment
26 April, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has launched the first FDA-approved home VPAP COPD treatment device into the US market.
STA cleared to market C. difficile treatment
26 April, 2013 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has won approval to market fidaxomicin - the C. difficile treatment licensed from Optimer Pharmaceuticals - in Australia.
Phylogica granted EU Phylomer patent
25 April, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has received a European patent covering the use of Phylomer peptides from its libraries to treat ischemic conditions including stroke and ARDS.
Prima names new advisors for CVac programs
24 April, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has appointed oncology experts Dr Holbrook Kohrt and Dr Pamela Klein as clinical advisors for its cancer vaccine programs.
Pharmaxis shares plunge on new Bronchitol setback
24 April, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has revealed a phase III trial of Bronchitol in bronchiectasis failed to meet its primary goal, sending its share price falling 45%.
Alchemia lands discovery deal with AstraZeneca
23 April, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has entered a small molecule drug discovery collaboration with AstraZeneca based on the former’s VAST chemistry platform.
Registration deadline looming for R&D Tax Incentive
23 April, 2013The registration of research and development (R&D) activities, under the R&D Tax Incentive, closes next week for the 2011-12 year.
Bionomics initiates manufacturing of tumour drug
23 April, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has contracted Lonza to produce tumour drug candidate BNC101 ahead of clinical trials anticipated for 2014.
Swedish agencies to trial Bioniche E. coli vaccine
19 April, 2013 by Dylan Bushell-EmblingSwedish government agencies will incorporate Bioniche’s (ASX:BNC) E. coli O157 cattle vaccine in its research into limiting human infection by verotoxigenic E. coli.
Novogen’s largest shareholder leaves board
19 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) non-executive director Josiah Austin has resigned to avoid having to fly from the US to Australia for monthly board meetings.
Starpharma secures dendrimer patents
18 April, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has been granted three new US patents for its dendrimer drug delivery platform and will soon pick up a patent in China.
Pharma Patent Review releases draft report for comment
18 April, 2013The Draft Report of the Pharmaceutical Patent Review is now open for comment.
